CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+22.53%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$295M
AUM Growth
+$295M
(+19%)
Cap. Flow
+$10.2M
Cap. Flow
% of AUM
3.44%
Top 10 Holdings %
Top 10 Hldgs %
32.39%
Holding
456
New
65
Increased
317
Reduced
38
Closed
9
Top Buys
| 1 |
NVIDIA
NVDA
|
$7.81M |
| 2 |
PayPal
PYPL
|
$4.77M |
| 3 |
STAAR Surgical
STAA
|
$3.64M |
| 4 |
Chipotle Mexican Grill
CMG
|
$3.46M |
| 5 |
Microsoft
MSFT
|
$3.33M |
Top Sells
| 1 |
iQIYI
IQ
|
$7.64M |
| 2 |
Pinduoduo
PDD
|
$6.59M |
| 3 |
ON Semiconductor
ON
|
$4.45M |
| 4 |
Apple
AAPL
|
$3.07M |
| 5 |
Rambus
RMBS
|
$2.77M |
Sector Composition
| 1 | Technology | 38.43% |
| 2 | Consumer Discretionary | 23.55% |
| 3 | Healthcare | 18.31% |
| 4 | Communication Services | 8.83% |
| 5 | Financials | 4.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PSTX
401
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $3.59K | ﹤0.01% |
1,164
+290
| +33% | +$893 |
|
|
TVRD
402
Tvardi Therapeutics, Inc. Common Stock
TVRD
$277M
| $3.57K | ﹤0.01% |
728
+182
| +33% | +$894 |
|
403
Foghorn Therapeutics
FHTX
$298M
| $3.51K | ﹤0.01% |
566
+141
| +33% | +$874 |
|
404
Immuneering
IMRX
$255M
| $3.48K | ﹤0.01% |
358
+90
| +34% | +$874 |
|
405
Generation Bio
GBIO
$40.3M
| $3.47K | ﹤0.01% |
808
+204
| +34% | +$877 |
|
406
MeiraGTx Holdings
MGTX
$587M
| $3.4K | ﹤0.01% |
657
+202
| +44% | +$1.04K |
|
407
Adicet Bio
ACET
$61.1M
| $3.35K | ﹤0.01% |
581
+146
| +34% | +$841 |
|
|
IMAB
408
I-MAB
IMAB
$357M
| $3.2K | ﹤0.01% |
925
+372
| +67% | +$1.29K |
|
|
CMPS
409
Compass Pathways
CMPS
$434M
| $3.19K | ﹤0.01% |
321
+81
| +34% | +$804 |
|
|
GRTS
410
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $3.14K | ﹤0.01% |
1,130
+283
| +33% | +$787 |
|
|
EXAI
411
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $3.11K | ﹤0.01% |
587
+220
| +60% | +$1.17K |
|
412
Xeris Biopharma Holdings
XERS
$1.28B
| $3K | ﹤0.01% |
1,842
+461
| +33% | +$751 |
|
413
PMV Pharmaceuticals
PMVP
$79M
| $2.95K | ﹤0.01% |
618
+154
| +33% | +$735 |
|
|
OPTN
414
DELISTED
OptiNose
OPTN
| $2.91K | ﹤0.01% |
1,509
+393
| +35% | +$758 |
|
415
Kezar Life Sciences
KZR
$28M
| $2.9K | ﹤0.01% |
927
+232
| +33% | +$726 |
|
416
UroGen Pharma
URGN
$904M
| $2.89K | ﹤0.01% |
313
+79
| +34% | +$730 |
|
417
Cartesian Therapeutics
RNAC
$256M
| $2.88K | ﹤0.01% |
2,074
+520
| +33% | +$723 |
|
418
Quantum-Si Incorporated
QSI
$219M
| $2.86K | ﹤0.01% |
1,624
+406
| +33% | +$714 |
|
419
Altimmune
ALT
$331M
| $2.82K | ﹤0.01% |
668
+169
| +34% | +$713 |
|
420
Century Therapeutics
IPSC
$41.1M
| $2.77K | ﹤0.01% |
799
+200
| +33% | +$694 |
|
421
Inovio Pharmaceuticals
INO
$137M
| $2.77K | ﹤0.01% |
3,380
+845
| +33% | +$693 |
|
|
CNTA
422
Centessa Pharmaceuticals
CNTA
$2.32B
| $2.74K | ﹤0.01% |
712
+179
| +34% | +$689 |
|
423
ALX Oncology
ALXO
$55.2M
| $2.5K | ﹤0.01% |
552
+138
| +33% | +$624 |
|
424
Annexon
ANNX
$227M
| $2.49K | ﹤0.01% |
646
+162
| +33% | +$624 |
|
425
Fulcrum Therapeutics
FULC
$347M
| $2.38K | ﹤0.01% |
836
+307
| +58% | +$875 |
|